Brought to you by 
Genentech gets RAF inhibitor HM95573 from Hanmi
20 Sep 2017
Executive Summary
Hanmi Pharmaceutical Co. Ltd. licensed Roche's Genentech Inc. exclusive worldwide rights (excluding South Korea) to develop and sell its Phase I HM95573, a pan-Raf inhibitor for solid tumors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech gets RAF inhibitor HM95573 from Hanmi
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice